Boston Spotlights

biotech news boston

Boston is a booming biotech hub, always expanding in innovative technologies and new discoveries in the biotech and biopharma organizations. The more health and technology developments grow, the more biotech news Boston increases as well, as an increasing number of news resources provide vital information to various audiences.

So stay in the know of the top biotech news Boston provides each day by subscribing to Big4Bio:Boston ,and discover the many life science events, podcasts, leadership changes, fundings, job opportunities and more.

Spotlight: Cerevance Raises $45 Million to Advance Therapeutics Against Novel CNS Targets

/

by Marie Daghlian Cerevance has raised $45 million in a series B financing to continue deploying its platform to identify novel therapeutic targets for central nervous system diseases, and advance a pipeline of therapies for Parkinson’s disease, Alzheimer’s disease, and neuroinflammation. New investors GV, Bill Gates, and Foresite Capital joined previous investors Takeda Ventures, the […]

Read More

Spotlight: Biotech Companies in the “Big 3” Regions Rake in the Cash

/

  BioWeekSF will soon be here again — January 5-10, 2019 — the week of the J.P. Morgan Healthcare Conference and 20 other events and forums. In preparation, the week’s premium online guide, BioWeekSF.com, is showcasing a series of reports and other resources focusing on financing and dealmaking. This feature is from DealForma, the biopharma database providing you […]

Read More

Spotlight: What Small and Emerging Companies Need When Entering Into Dealmaking Discussions

/

BioWeekSF will soon be here again — January 6-11, 2019 — the week of the J.P. Morgan Healthcare Conference and 20 other events and forums. In preparation,  the week’s premium online guide, BioWeekSF.com, is sponsoring a series of viewpoints and more from leaders and professionals involved in life sciences/healthcare dealmaking. As Chair of Foley Hoag’s Licensing & […]

Read More

Spotlight: First Coast Tech Hubs Gather @ RESI Boston

/

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series The First Coast Innovator’s Gathering is a new component of the Redefining Early Stage Investments (RESI) Conference Series which was requested by the investors and strategic channel partners who routinely attend RESI. Many of these partners wanted LSN to bring the “earliest stage” […]

Read More

Event Recap: RESI in Boston – The Power of Partnering and Networking for Healthcare Innovators in 2018

/

By Marie Daghlian Despite unseasonably cold and rainy weather, more than 800 attendees from 38 states and 25 countries showed up at the Boston Marriott Copley Place for a day of networking, partnering, and workshops at the RESI Global Partnering Conference—Redefining Early Stage Investments—held June 4 during BIO2018 week. RESI has become an important venue […]

Read More

Spotlight: BIOWeek:Boston 2018

/

BIOWeek:Boston 2018 The Complete Guide to the Week of the BIO International Convention June 3-8, 2018 Big3Bio Releases The First Version of BIOWeek:Boston 2018, The Complete Guide to the Week of #BIO2018       SAN FRANCISCO, CA–(May 25, 2018)–Big3Bio, the leading aggregator service for the top biotech hubs in the US—Boston, San Francisco Bay […]

Read More

May Financial Focus: Boston Area a Hot-Bed for Biopharma Startups

/

By Marie Daghlian VC funding for Boston area biotech companies is on fire and its momentum shows no signs of slowing up. Boston area biotech and health-related companies raised $1.58 billion in 32 deals in the first quarter of 2018. That compares favorably with the $1.59 billion raised in Q4 2017 in 42 deals, and […]

Read More

Spotlight Q&A with Rob Neville, CEO, Savara Pharmaceuticals

/

About Savara Pharmaceuticals: Savara Inc. (NASDAQ: SVRA) is an orphan lung disease company. Savara’s pipeline comprises a number of late stage therapeutics each targeting difficult to treat lung diseases. For people not familiar with Savara, can you provide a brief overview and focus? Neville: Savara was founded in 2008 and based in Austin, Texas. Our […]

Read More

Spotlight: Virginia Capezio from TriNet Talks About How Biotech Companies Can Tackle the Tough HR Considerations in 2018

/

Virginia Capezio is a senior human resources consultant with TriNet, a company that provides full-service HR solutions to small and midsize businesses. Here, Virginia talks about the changing landscape of the biotech workplace, how broader trends may be affecting the environment and the big HR issues biotech companies should be thinking about in the new […]

Read More

From Candidate Selection to Market: Navigating Challenges in Biotechnology

/

  Not every drug development program follows a similar path to regulatory approval. Don’t miss out on this Charles River workshop which will bring together industry professionals to provide guidance on key components and considerations for designing and optimizing your drug development program. The workshop will include interactive sessions to discuss how to attract investors, […]

Read More

Spotlight: Fostering a Culture of Innovation to Drive Growth

/

Develop an Innovative Culture As companies look to generate new growth, many are concerned that their culture may be inhibiting them from achieving their goals. While many people believe a stronger culture that supports innovation will lead to growth, most lack clarity about what the true impact improving culture has on innovation and what types […]

Read More

Charles River 23rd Annual Biotechnology-Derived Therapeutics Perspectives on Nonclinical Development Symposium

/

The Charles River 23rd Annual Biotechnology-Derived Therapeutics Perspectives on Nonclinical Development symposium will be held September 11-13, 2017 at Cape Rey Resort, Carlsbad, CA. This three-day symposium with five sessions has a jam-packed agenda with case study presentations from industry leaders from Bluebird, Janssen, Pfizer and Amgen in the nonclinical development of biotherapeutics. Don’t miss out on […]

Read More

Advancing Rare Disease Drug Discovery: Navigating the Path to an IND

/

Symposium Overview: Therapies to treat rare and undiagnosed diseases are in high demand in a favorable regulatory environment. Thus, it is critically important to optimize the discovery and development of such therapies by creating – and following – the most efficient path to an investigational new drug (IND) filing. How do we do just that? […]

Read More